Pharmacology
FDA Refuses Autism Drug Application
By Johnson & Johnson Pharmaceutical Research & Development
May 21, 2005, 10:23

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced that it has received a not approvable letter from the U.S. Food and Drug Administration (FDA) regarding a Supplemental New Drug Application (sNDA) for RISPERDAL(R) (risperidone) in the treatment of autism.

Recognizing the unmet need in this area is great, J&JPRD is evaluating the FDA's letter and will determine appropriate next steps.

All rights reserved by www.rxpgnews.com